Tailor-Made vaccine aims to train immune system against cancer

NCT ID NCT07680582

First seen Jul 02, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combination and see how well it triggers an immune response. Participants include those who have had surgery for their cancer or have advanced disease, and the trial will also look for early signs that the vaccine might help prevent the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
personalized cancer vaccine (ABO2109) and toripalimab (anti-PD-1 antibody)
What this could lead to
If successful, this could pave the way for a personalized vaccine that trains the immune system to fight residual cancer cells after surgery, potentially reducing recurrence risk.
What could go wrong
This is a very early (Phase 1) study with only 60 participants, so safety and effectiveness are not yet proven. The vaccine is personalized, making it complex and costly, and it may not work for all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.